



## OPEN ACCESS

EDITED AND REVIEWED BY  
Nurit Hollander,  
Tel Aviv University, Israel

## \*CORRESPONDENCE

Yongmei Jiang  
✉ jiang\_ym@scu.edu.cn  
Jinke Li  
✉ jinkeli@scu.edu.cn  
Qintong Li  
✉ liqintong@scu.edu.cn

RECEIVED 19 March 2024

ACCEPTED 08 April 2024

PUBLISHED 17 April 2024

## CITATION

Mai J, Wu L, Yang L, Sun T, Liu X, Yin R, Jiang Y, Li J and Li Q (2024) Corrigendum: Therapeutic strategies targeting folate receptor  $\alpha$  for ovarian cancer. *Front. Immunol.* 15:1403324. doi: 10.3389/fimmu.2024.1403324

## COPYRIGHT

© 2024 Mai, Wu, Yang, Sun, Liu, Yin, Jiang, Li and Li. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Therapeutic strategies targeting folate receptor $\alpha$ for ovarian cancer

Jia Mai<sup>1</sup>, Limei Wu<sup>1,2</sup>, Ling Yang<sup>1</sup>, Ting Sun<sup>3</sup>, Xiaojuan Liu<sup>1</sup>, Rutie Yin<sup>1</sup>, Yongmei Jiang<sup>1\*</sup>, Jinke Li<sup>1\*</sup> and Qintong Li<sup>1\*</sup>

<sup>1</sup>Department of Laboratory Medicine, Obstetrics & Gynecology and Pediatrics, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Center of Growth, Metabolism and Aging, State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, Sichuan, China,

<sup>2</sup>Department of Obstetrics and Gynecology, Chengdu Second People's Hospital, Chengdu, Sichuan, China, <sup>3</sup>Department of Clinical Laboratory, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China

## KEYWORDS

ovarian cancer, folate receptor  $\alpha$ , FOLR1, mirvetuximab soravtansine, MIRV, Elahere, antibody-drug conjugate, ADC

## A Corrigendum on

### Therapeutic strategies targeting folate receptor $\alpha$ for ovarian cancer

By Mai J, Wu L, Yang L, Sun T, Liu X, Yin R, Jiang Y, Li J and Li Q (2023). *Front. Immunol.* 14:1254532. doi: 10.3389/fimmu.2023.1254532

In the published article, there was an error in [Figure 1](#) as published. PCTF is a symporter that transport H<sup>+</sup> ion together with the folate transporter, we made a mistake with the direction of one arrow, by making it like PCFT is portrayed as an antiporter. The corrected [Figure 1](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 1

The uptake of extracellular folate is achieved mainly through three types of folate transporters. (1) RFC, an anion antiporter that uses a gradient of higher organic phosphate in the cell to transport folate into the cell while transporting organic phosphate out of the cell, (2) PCFT, a proton-coupled transporter, (3) folate receptor family (only FR $\alpha$  is shown). They transfer folate through endocytosis in selected tissues.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.